The Zhitong Finance App learned that on April 29, Repertoire Immune Medicines, a biotechnology company that pioneered the discovery and development of programmable T-cell-targeted immune drugs, announced that it had reached a cooperation agreement with BMY.US (BMY.US) to develop “tolerable vaccines” for 3 types of autoimmune diseases. The collaboration aims to develop effective, selective, and long-lasting treatments for patients with autoimmune diseases by resetting the immune system.
Under the terms of the agreement, Repertoire will receive $65 million in advance payments and up to $1.8 billion in advance payments to achieve development, regulatory and commercial milestones, in addition to tiered royalties.